WallStreetZenWallStreetZen

NASDAQ: SLDB
Solid Biosciences Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for SLDB

Based on 6 analysts offering 12 month price targets for Solid Biosciences Inc

Min Forecast
$16.00+133.58%
Avg Forecast
$20.50+199.27%
Max Forecast
$26.00+279.56%

Should I buy or sell SLDB stock?

Based on 6 analysts offering ratings for Solid Biosciences Inc.

Strong Buy
Strong Buy
3 analysts 50%
Buy
3 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although SLDB's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates SLDB as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -6.47% per year. Learn More

Be the first to know when Wall Street analysts revise their SLDB stock forecasts and price targets.

SLDB stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-09-16
lockedlocked$00.00+00.00%2026-09-14
lockedlocked$00.00+00.00%2026-08-27Find Out Why
lockedlocked$00.00+00.00%2026-08-21Find Out Why
lockedlocked$00.00+00.00%2026-05-18
Piper Sandler
Bottom 4%
4
Strong BuyMaintains$18.00+162.77%2026-05-13

1 of 1

Forecast return on equity

Is SLDB forecast to generate an efficient return?

Company
-3.12%
Industry
21.83%
Market
168.15%
SLDB's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is SLDB forecast to generate an efficient return on assets?

Company
-2.77%
Industry
23.8%
SLDB is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SLDB earnings per share forecast

What is SLDB's earnings per share in the next 3 years based on estimates from 16 analysts?

Avg 1 year Forecast
-$1.80
Avg 2 year Forecast
-$1.77
Avg 3 year Forecast
-$1.37

SLDB revenue forecast

What is SLDB's revenue in the next 3 years based on estimates from 14 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$12.2M
Avg 3 year Forecast
$112.5M

SLDB vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SLDB$6.85$20.50+199.27%Strong Buy
FTH$28.35$57.00+101.06%Strong Buy
HELP$11.70$45.00+284.62%Strong Buy
WVE$3.78$19.00+402.65%Strong Buy
ACHV$7.24$14.00+93.37%Strong Buy
View Top Biotech Stocks

Solid Biosciences Stock Forecast FAQ

Is Solid Biosciences Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: SLDB) stock is to Strong Buy SLDB stock.

Out of 6 analysts, 3 (50%) are recommending SLDB as a Strong Buy, 3 (50%) are recommending SLDB as a Buy, 0 (0%) are recommending SLDB as a Hold, 0 (0%) are recommending SLDB as a Sell, and 0 (0%) are recommending SLDB as a Strong Sell.

If you're new to stock investing, here's how to buy Solid Biosciences stock.

What is SLDB's earnings growth forecast for 2026-2028?

(NASDAQ: SLDB) Solid Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.13%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.53%.

Solid Biosciences's earnings in 2026 is -$207,099,000.On average, 16 Wall Street analysts forecast SLDB's earnings for 2026 to be -$192,597,972, with the lowest SLDB earnings forecast at -$251,035,727, and the highest SLDB earnings forecast at -$174,509,075. On average, 16 Wall Street analysts forecast SLDB's earnings for 2027 to be -$189,488,441, with the lowest SLDB earnings forecast at -$252,193,760, and the highest SLDB earnings forecast at -$146,362,450.

In 2028, SLDB is forecast to generate -$146,887,854 in earnings, with the lowest earnings forecast at -$230,126,806 and the highest earnings forecast at -$54,041,520.

What is SLDB's revenue growth forecast for 2026-2028?

(NASDAQ: SLDB) Solid Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.32%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.51%.

Solid Biosciences's revenue in 2026 is $0.On average, 14 Wall Street analysts forecast SLDB's revenue for 2026 to be $0, with the lowest SLDB revenue forecast at $0, and the highest SLDB revenue forecast at $0. On average, 14 Wall Street analysts forecast SLDB's revenue for 2027 to be $1,307,397,327, with the lowest SLDB revenue forecast at $0, and the highest SLDB revenue forecast at $9,254,610,292.

In 2028, SLDB is forecast to generate $12,062,839,275 in revenue, with the lowest revenue forecast at $2,709,688,989 and the highest revenue forecast at $26,140,440,772.

What is SLDB's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: SLDB) forecast ROA is -2.77%, which is lower than the forecast US Biotechnology industry average of 23.8%.

What is SLDB's Price Target?

According to 6 Wall Street analysts that have issued a 1 year SLDB price target, the average SLDB price target is $20.50, with the highest SLDB stock price forecast at $26.00 and the lowest SLDB stock price forecast at $16.00.

On average, Wall Street analysts predict that Solid Biosciences's share price could reach $20.50 by Sep 16, 2027. The average Solid Biosciences stock price prediction forecasts a potential upside of 199.27% from the current SLDB share price of $6.85.

What is SLDB's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: SLDB) Solid Biosciences's current Earnings Per Share (EPS) is -$1.91. On average, analysts forecast that SLDB's EPS will be -$1.80 for 2026, with the lowest EPS forecast at -$2.34, and the highest EPS forecast at -$1.63. On average, analysts forecast that SLDB's EPS will be -$1.77 for 2027, with the lowest EPS forecast at -$2.35, and the highest EPS forecast at -$1.37. In 2028, SLDB's EPS is forecast to hit -$1.37 (min: -$2.15, max: -$0.50).

What is SLDB's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: SLDB) forecast ROE is -3.12%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.